#Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizumab. Not RCT. Looked safe & effective but too small to know if blindness etc are increased. Don’t suggest you try this at home...yet! @RheumNow @eular_org #EULAR2022 OP0185

#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷‍♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022

Positive study NUT when to use the Rx? PMR RCTof 1 g #rituximab once. Over 1 yr with more steroid free remission - curves separate by 21 weeks (steroids off) POS0269 @RheumNow @eular_org #EULAR2023 when to use it-COVID risk, ?prefer IL6i

ARIAA: saw 18m results #EULAR2022 (alluded to at #ACR21) High-risk ACPA+ clinically suspect arthralgias Didn't progress to arthritis: after 6m abatacept: 92% vs 65% 12m after abatacept stopped: 65% vs 43% (tighter at points) How to pick those that benefit? POS0531 @RheumNow https://t.co/dkf1jU5gx7

As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here are my key Psoriatic Arthritis topics and updates from EULAR 2022 https://t.co/KNGGUJuukg @RheumNow

WATCH: #EULAR2022 - Day 3 Faculty Panel Recap Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.https://t.co/ExCXY6Xbl4@Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/tIB8QrdYuI

Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-controlled study Met primary endpoint SRI response across all doses No death, MACE, VTE, systemic infections @RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee

Sarilumab in pts with relapsing PMR - Phase 3 trial Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%) Less flare occurrences Sarilumab noted to have higher incidences of neutropenia, arthralgia @RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3